Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2020-03-23 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
独立董事候选人声明（王云龙）
Board/Management Information Classification · 95% confidence The document is a detailed declaration by an independent director candidate of a company, affirming compliance with various legal and regulatory requirements related to independence and qualifications. It is a formal statement related to board/management matters, specifically concerning the appointment or candidacy of an independent director. There is no financial data, no report publication, no voting results, or other types of filings. This fits best under Board/Management Information (MANG), which covers announcements of changes or declarations related to the company's board of directors or senior management.
2020-03-23 Chinese
关于召开2019年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2019 Annual General Meeting (AGM) of 华兰生物工程股份有限公司, including the date, time, location, voting procedures (both in-person and online), agenda items to be discussed and voted on, and instructions for shareholders. It includes information about the proposals to be considered, such as the 2019 annual report, financial statements, profit distribution, appointment of auditors, and election of independent directors. The document is a formal announcement inviting shareholders to attend and vote at the AGM, rather than the actual annual report or voting results. It does not contain financial statements or results but rather the meeting logistics and agenda. Therefore, it fits the category of AGM Information (AGM-R).
2020-03-23 Chinese
2019年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) for 华兰生物工程股份有限公司 covering the fiscal year from January 1, 2019 to December 31, 2019. It includes detailed audit opinions, key audit matters, and extensive financial statements such as consolidated balance sheets, income statements, cash flow statements, and changes in shareholders' equity. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content focuses on the auditor's opinion, audit procedures, and detailed financial data, which aligns with the definition of an Audit Report / Information filing. It is not an Annual Report (10-K) because it lacks management discussion and broader company activity coverage beyond the audit and financial statements. It is not a Regulatory Filing or Report Publication Announcement because it contains the full audit report and financial statements, not just a notice or certification. Therefore, the document is best classified as an Audit Report / Information (AR). FY 2019
2020-03-23 Chinese
独立董事候选人关于参加独立董事培训并取得独立董事资格证书的承诺函（一）
Board/Management Information Classification · 95% confidence The document is a written commitment letter from a candidate for independent director, Liu Wanli, stating the intention to attend training and obtain the independent director qualification certificate as required by Shenzhen Stock Exchange regulations. It references the company's board meeting and the upcoming 2019 annual general meeting notice but does not contain financial data, audit information, or any report content. It is an announcement related to board/management information, specifically about an independent director candidate's qualification status and commitment. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on management personnel information, not a report or announcement of voting results or other categories.
2020-03-23 Chinese
独立董事提名人声明（二）
Board/Management Information Classification · 100% confidence The document is a public statement from the board of directors nominating an independent director candidate for the company's board. It details the qualifications, compliance with regulatory requirements, and independence of the nominee. There is no financial data, no discussion of financial results, no mention of shareholder voting results, or any other report type. The document is clearly related to board/management information, specifically about a board nomination. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is sufficient and the content is substantive, not a mere announcement or certification, so it is not RNS or RPA.
2020-03-23 Chinese
2019年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2019 年年度报告摘要" which translates to "2019 Annual Report Summary". It contains detailed financial data for the year 2019, including revenue, net profit, earnings per share, and asset totals. It also discusses business operations, product lines, industry position, and accounting policy changes. The length of the document (over 13,000 characters) and the presence of comprehensive financial and operational information indicate this is a full annual report or a substantial summary of it, not just an announcement or a brief summary. The document is not a transcript, call, or management change notice. It is clearly a formal annual report document from a Chinese company, consistent with the definition of an Annual Report (10-K). FY 2019
2020-03-23 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.